Polymorphic forms and co-crystals of a c-Met inhibitor
AssigneeAmgen Inc.
InventorsDavid Bauer, Matthew Bio, Melanie Cooke, Katrina W. Copeland, Matthew Peterson, Michele Potashman, Roman Shimanovich, Helming Tan
Life of this patent
Estimating the term…
Abstract
Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.
Claims3
A free base form of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, wherein the free base form is a monohydrate form.
Dependencies are inferred from the claim text.